Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 20/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12240027 | 0.93 | KHK (1.00) | KHK | |
| SCHEMBL2552469 | 0.80 | KHK (1.00) | KHK | |
| Formic Acid SCHEMBL2552003 | 0.79 | KHK (0.88) | KHK | |
| Formic Acid SCHEMBL2546135 | 0.78 | KHK (0.88) | KHK | |
| SCHEMBL12240024 | 0.78 | KHK (1.00) | KHK | |
| Hydrochloric Acid SCHEMBL2551539 | 0.77 | KHK (0.97) | KHK | |
| SCHEMBL12240026 | 0.77 | KHK (1.00) | KHK | |
| SCHEMBL2553212 | 0.77 | KHK (1.00) | KHK | |
| Trifluoroacetic Acid SCHEMBL2550034 | 0.74 | KHK (0.82) | KHK | |
| SCHEMBL12240019 | 0.73 | KHK (1.00) | KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771375-B2 | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-26 | — | — | US | disclosed |
| US-20140336170-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-11-13 | — | — | US | disclosed |
| US-8822447-B2 | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-02 | — | — | US | disclosed |
| EP-2560962-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | Janssen Pharmaceutica NV (BE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133750-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263559-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336170-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | KHK, GCK, GCKR | KHK 1/4885 |
| US-20110263559-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | KHK, GCK, GCKR | KHK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.